Rankings / Metabolic Health

Mazdutide (IBI362)

Metabolic Health · GLP-1/glucagon agonist (dual)

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

glp-1investigational
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Mazdutide (IBI362) as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

Innovent Biologics; Chinese-approved for obesity and T2D in 2025.

Studied, labeled, or reported-use context: 4-9 mg SC weekly — Approved in China (June 2025) for chronic weight management; FDA filing TBD; not individualized guidance.

What the evidence says

Innovent Biologics; Chinese-approved for obesity and T2D in 2025. GLORY-1 Phase 3 (China, n>600) showed -16.8% body weight at 32 weeks at 9 mg dose. Meaningful for biohacker readers because it reaches similar magnitude to tirzepatide and is already prescribed in China while Western markets wait. Particular interest for MASLD/NAFLD due to hepatic glucagon effects. A Jul 2026 BMJ network meta-analysis (262 RCTs, n=99,791) of anti-obesity drugs placed mazdutide among the emerging agents (with ecnoglutide and retatrutide) projected to match or exceed tirzepatide's weight loss (13.1-14.6% at one year vs lifestyle alone), though rated very low to low certainty given its indirect, largely China-only trial base.

Mechanism

Dual GLP-1 and glucagon receptor agonist; glucagon arm increases hepatic fat oxidation and energy expenditure (similar mechanism to survodutide); developed by Innovent (China) under license from Lilly's OXM3

Studied, labeled, or reported dose & route

4-9 mg SC weekly

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Mazdutide (IBI362)'s effects?
Read Off Label rates the evidence for Mazdutide (IBI362) as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). Innovent Biologics; Chinese-approved for obesity and T2D in 2025.
What safety findings are reported for Mazdutide (IBI362)?
Mazdutide (IBI362) has a med risk profile in the database. Med (similar GI profile to GLP-1 class) Legal status: Approved in China (June 2025) for chronic weight management; FDA filing TBD.
What doses or routes are reported for Mazdutide (IBI362)?
4-9 mg SC weekly This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Mazdutide (IBI362) work?
Dual GLP-1 and glucagon receptor agonist; glucagon arm increases hepatic fat oxidation and energy expenditure (similar mechanism to survodutide); developed by Innovent (China) under license from Lilly's OXM3

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.